New late‐emphasis and combination tests based on infimum and supremum logrank statistics with application in oncology trials - Inserm - Institut national de la santé et de la recherche médicale Access content directly
Journal Articles Statistics in Medicine Year : 2023

New late‐emphasis and combination tests based on infimum and supremum logrank statistics with application in oncology trials

Abstract

Immunotherapy cancer clinical trials routinely feature an initial period during which the treatment is given without evident therapeutic benefit, which may be followed by a period during which an effective therapy reduces the hazard for event occurrence. The nature of this treatment effect is incompatible with the proportional hazards assumption, which has prompted much work on the development of alternative effect measures of frameworks for testing. We consider tests based on individual and combination of early- and late-emphasis infimum and supremum logrank statistics, describe how they can be implemented, and evaluate their performance in simulation studies. Through this work and illustrative applications we conclude that this class of test statistics offers a new and powerful framework for assessing treatment effects in cancer clinical trials involving immunotherapies.
Fichier principal
Vignette du fichier
Statistics in Medicine - 2023 - Boher.pdf (1.89 Mo) Télécharger le fichier
Origin : Publication funded by an institution
Licence : CC BY - Attribution

Dates and versions

inserm-04546644 , version 1 (15-04-2024)

Identifiers

Cite

Jean Marie Boher, Thomas Filleron, Pierre Bunouf, Richard J Cook. New late‐emphasis and combination tests based on infimum and supremum logrank statistics with application in oncology trials. Statistics in Medicine, 2023, 42, pp.1981 - 1994. ⟨10.1002/sim.9709⟩. ⟨inserm-04546644⟩
24 View
6 Download

Altmetric

Share

Gmail Facebook X LinkedIn More